Efficacy and predictors of virological non‐suppression in Thailand's rollout of dolutegravir‐based first‐line antiretroviral therapy: A nationwide cohort analysis
HIV Medicine · 2025
DOI: 10.1111/hiv.70178 ↗Kurz gefasst
Fachartikel in der Zeitschrift HIV Medicine, 2025. Verfasst von Napon Hiranburana und 12 weiteren Autor:innen. Beteiligte Einrichtung: HIVNAT, Thai Red Cross AIDS and Infectious Diseases Research Centre, Bangkok, Thailand. Hauptthemen laut MEDLINE: Heterocyclic Compounds, 3-Ring, Piperazines, Pyridones, HIV Infections. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NIAAA NIH HHS, NIMH NIH HHS.
Abstract (Originalsprache)
Objective
To evaluate real‐world outcomes of dolutegravir (DTG)‐based first‐line antiretroviral therapy (ART) among people with HIV in Thailand, where baseline HIV‐1 RNA and resistance testing is not routinely available.
Methods
This retrospective cohort study enrolled ART‐naive Thai people with HIV aged ≥15 years who initiated DTG‐based ART between 2020 and 2023 under the national Universal Health Coverage programme. People with HIV with ≥1 post‐baseline HIV viral load (VL) measurement were included. Virological non‐suppression (VNS) was defined as VL ≥1000 copies/mL after ≥6 months of ART. The primary outcome was the proportion achieving virological suppression (VL
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- HIVNAT, Thai Red Cross AIDS and Infectious Diseases Research Centre, Bangkok, Thailand.
- Center of Excellence in Tuberculosis, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
- Research Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
- The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.
- Division of AIDS and STI, Department of Disease Control, Ministry of Public Health, Nonthaburi, Thailand.
- Taksin Hospital, Bangkok, Thailand.
ORCID-Profile: Napon Hiranburana, Jiratchaya Sophonphan, Stephen J Kerr, Cheewanan Lertpiriyasuwat, Sairat Noknoy, Supunnee Jirajariyavej, Ploenchan Chetchotisakd, Chureeratana Bowonwatanuwong, Kiat Ruxrungtham, Opass Putcharoen, Anchalee Avihingsanon
Förderung
- NHLBI NIH HHS
- NIAAA NIH HHS
- NIMH NIH HHS
- U.S. National Institute of Health's (NIH) National Institute of Allergy and Infectious Diseases
- NIAID NIH HHS
- NIDDK NIH HHS
- NIDA NIH HHS
- FIC NIH HHS
Zitieren
APA
Hiranburana, N., Sophonphan, J., Kerr, S. J., Lertpiriyasuwat, C., Noknoy, S., Jirajariyavej, S., Fujitnirun, C., Chetchotisakd, P., Lolekha, R., Bowonwatanuwong, C., Ruxrungtham, K., Putcharoen, O., & Avihingsanon, A. (2025). Efficacy and predictors of virological non‐suppression in Thailand's rollout of dolutegravir‐based first‐line antiretroviral therapy: A nationwide cohort analysis. HIV Medicine. https://doi.org/10.1111/hiv.70178
Vancouver
Hiranburana N, Sophonphan J, Kerr SJ, Lertpiriyasuwat C, Noknoy S, Jirajariyavej S, et al. Efficacy and predictors of virological non‐suppression in Thailand's rollout of dolutegravir‐based first‐line antiretroviral therapy: A nationwide cohort analysis. HIV Medicine. 2025. doi:10.1111/hiv.70178
BibTeX
@article{Hiranburana2025,
author = {Hiranburana, Napon and Sophonphan, Jiratchaya and Kerr, Stephen J and Lertpiriyasuwat, Cheewanan and Noknoy, Sairat and Jirajariyavej, Supunnee and Fujitnirun, Chris and Chetchotisakd, Ploenchan and Lolekha, Rangsima and Bowonwatanuwong, Chureeratana and Ruxrungtham, Kiat and Putcharoen, Opass and Avihingsanon, Anchalee},
title = {Efficacy and predictors of virological non‐suppression in Thailand's rollout of dolutegravir‐based first‐line antiretroviral therapy: A nationwide cohort analysis},
journal = {HIV Medicine},
year = {2025},
doi = {10.1111/hiv.70178}
}
EUVIMED